Open AccessPhentermine-topiramate: First combination drug for obesity
Author(s) -
Jagjit Singh,
Rajiv Kumar
Publication year - 2015
Publication title -
international journal of applied and basic medical research/international journal of applied and basic medical research
Language(s) - English
Resource type - Journals
eISSN - 2248-9606
pISSN - 2229-516X
DOI - 10.4103/2229-516x.157177
Subject(s) - phentermine , orlistat , topiramate , medicine , obesity , weight loss , overweight , drug , placebo , food and drug administration , management of obesity , pharmacology , psychiatry , alternative medicine , epilepsy , pathology
Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combination of phentermine immediate release and topiramate extended release in 2012 for treatment of obese patients or overweight patients with comorbid conditions. The new drug has shown significant weight loss compared with placebo for a period up to 2 years.